Search Result

Results for "

KY

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Acyltransferase (1) ADC Linker (1) Antibiotic (2) Apoptosis (2) Autophagy (2) Bacterial (1) CD28 (1) DNA/RNA Synthesis (1) Drug Derivative (1) Fungal (1) GSK-3 (1) Histamine Receptor (1) MAP4K (1) Organoid (2) PAK (2) Phosphatase (1) PI3K (2) Polo-like Kinase (PLK) (2) Ras (1) Small Interfering RNA (siRNA) (1) Wnt (7) β-catenin (3)
By Research Areas:	Cancer (10) Cardiovascular Disease (1) Infection (2) Inflammation/Immunology (4) Metabolic Disease (6) Neurological Disease (1)
Click Chemistry:	Alkynes (1)
Oligonucleotides:	Human Pre-designed siRNA Sets (1) siRNAs (1)

Inhibitors & Agonists

Inhibitory Antibodies

Natural
Products

Click Chemistry

Oligonucleotides

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-124156A

KY-02327 acetate	Wnt	Metabolic Disease
KY-02327 acetate, a metabolically stabilized KY-02061 analog, is a potent Dishevelled (Dvl)-CXXC5 interaction inhibitor. KY-02327 acetate shows an activating effect on the Wnt/β-catenin pathway, resulting in promotion of osteoblast differentiation .

HY-124745

KY-05009	MAP4K Wnt Apoptosis	Cancer
KY-05009 is an ATP-competitive Traf2- and Nck-interacting kinase (TNIK) inhibitor with a K_i of 100 nM. KY-05009 pharmacologically inhibits TGF-β1-induced epithelial-to-mesenchymal transition (EMT) in human lung adenocarcinoma cells. KY-05009 inhibits the protein expression of TNIK and transcriptional activity of Wnt target genes and induces apoptosis in cancer cells. KY-05009 exerts anti-cancer activity .

HY-120327

KY-226 2 Publications Verification	Phosphatase	Neurological Disease Metabolic Disease
KY-226 is a potent, selective, orally active and allosteric protein tyrosine phosphatase 1B (PTP1B) inhibitor with an IC₅₀ of 0.25 μM, and without PPARγ agonist activity. KY-226 exerts anti-diabetic and anti-obesity effects by enhancing insulin and leptin signaling, respectively. KY-226 also protects neurons from cerebral ischemic injury .

HY-147084

KY371	ADC Linker	Metabolic Disease Cancer
KY371 is a click chemistry reagent containing an alkyne group. KY371 is a broad-range glycosidase inhibitor. KY371 can combine with proteomic analysis of targeted protein to study glycosidases .

HY-13815

KY02111 5 Publications Verification	Wnt	Cardiovascular Disease
KY02111 is a canonical WNT signaling (β-catenin) inhibitor which promotes differentiation of hPSCs to cardiomyocytes. KY02111 can be used for the research of human cardiomyocyte regeneration .

HY-124764

KY-04031	PAK	Cancer
KY-04031 is a potent PAK4 inhibitor with IC₅₀ of 0.79 μM. KY-04031 binds to the ATP-binding pocket of PAK4. KY-04031 blocks tumor cell growth and invasion .

HY-124156

KY-02327	Wnt	Metabolic Disease
KY-02327, a metabolically stabilized KY-02061 analog, is a potent Dishevelled (Dvl)-CXXC5 interaction inhibitor. KY-02327 shows an activating effect on the Wnt/β-catenin pathway, resulting in promotion of osteoblast differentiation .

HY-167664

KY-455	Acyltransferase	Metabolic Disease
KY-455 is a novel inhibitor of acyl-CoA:cholesterol acyltransferase (ACAT). KY-455 inhibita rabbit intestinal, hepatic, macrophage and adrenal ACAT with IC₅₀ values of 0.4, 0.9, 2.9 and 4.1 μmol/L, respectively.

HY-113680

KY1022	Apoptosis Ras β-catenin Wnt	Cancer
KY1022 is a small molecule destabilizing Ras via targeting the Wnt/β-catenin pathway. KY1022 can inhibit cellular EMT, metastasis and apoptosis. KY1022 can be used for the research of metastatic colorectal cancer .

HY-117218

KY-04045	PAK	Cancer
KY-04045 is a PAK4 specific inhibitor (IC₅₀=8.7 μM) that can be used for the development of anticancer drugs targeting PAK4 .

HY-117842

KY 234	Histamine Receptor	Inflammation/Immunology
KY 234 is an orally effective inhibitor that targets thromboxane A2 production, with an IC₅₀ of 5 μM. KY 234 significantly inhibits leukotriene D4 (LTD4), histamine, and antigen-induced bronchoconstriction in guinea pigs, with IC₅₀ values of 6.0 mg/kg, 2.5 mg/kg, and 6.3 mg/kg, respectively .

HY-U00148

KY-556 1 Publications Verification N556	Drug Derivative	Inflammation/Immunology
KY-556 is a promising and orally-active pro-agent of disodium cromoglycate (DSCG) against allergic diseases.

HY-P99431

KY-1044 Alomfilimab; SAR 445256	CD28	Inflammation/Immunology Cancer
KY-1044 (Alomfilimab; SAR 445256) is a fully human IgG1 antibody targeting inducible costimulatory receptor (ICOS). KY-1044 depletes ICOS ^high cells via antibody-dependent cellular cytotoxicity (ADCC) through the engagement of FcgRIIIa. KY-1044 act as a costimulatory molecule on cells expressing lower ICOS levels, such as CD8 ⁺ T_Eff cells (through FcgR-dependent clustering). KY-1044 exploit the differential expression of ICOS on T-cell subtypes to improve the intratumoral immune contexture and restore an antitumor immune response .

HY-156418

KY386	DNA/RNA Synthesis	Cancer
KY386 is a potent, selective inhibitor of DHX33 helicase, with the IC₅₀ of 19 nM. KY386 inhibits U251-MG cells (DHX33-overexpressing cancer cell strain) with IC₅₀ of 20 nM.and shows potent anti-cancer activity and moderate metabolic stability .

HY-131447

KY19382 3 Publications Verification A3051	GSK-3 Wnt β-catenin	Metabolic Disease
KY19382 is a potent and orally active dual inhibitor of CXXC5-DVL and GSK3β, with IC₅₀s of 19 and 10 nM, respectively. KY19382 activates Wnt/β-catenin signaling through inhibitory effects on both CXXC5-DVL interaction and GSK3β activity. KY19382 can be used for the research of high fat diet (HFD) induced metabolic diseases .

HY-129914

Cefcanel daloxate KY-109 free base	Bacterial	Infection
Cefcanel daloxate (KY-109 (free base)) is an orally active cephalosporin prodrug against Gram-positive bacteria and *Haemophilus influenzae*. Cefcanel daloxate is promising for research of uremia .

HY-RS07479

KY Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
KY Human Pre-designed siRNA Set A contains three designed siRNAs for KY gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

KY Human Pre-designed siRNA Set A KY Human Pre-designed siRNA Set A

HY-102028

KY1220 3 Publications Verification	Wnt β-catenin	Cancer
KY1220 is a compound that destabilizes both β-catenin and Ras, via targeting the Wnt/β-catenin pathway; with an IC₅₀ of 2.1 μM in HEK293 reporter cells.

HY-10197

Wortmannin Maximum Cited Publications 129 Publications Verification SL-2052; KY-12420	Organoid PI3K Polo-like Kinase (PLK) Autophagy Antibiotic	Cancer
Wortmannin (SL-2052; KY-12420) is a potent, selective and irreversible PI3K inhibitor with an IC₅₀ of 3 nM. Wortmannin also blocks autophagy formation, and potently inhibits Polo-like kinase 1 (PlK1) and Plk3 with IC₅₀s of 5.8 and 48 nM, respectively .

HY-W164451

N-(2-hydroxy-2-phenylethyl)acetamide	Fungal	Infection
N-(2-hydroxy-2-phenylethyl)acetamide is isolated from the solid rice cultures of the endophytic fungus Diaporthe eucalyptorum KY-9. N-(2-hydroxy-2-phenylethyl)acetamide exhibits antifungal activities against Alternaria solani .

HY-10197R

Wortmannin (Standard)	Organoid PI3K Polo-like Kinase (PLK) Autophagy Antibiotic	Cancer
Wortmannin (Standard) is the analytical standard of Wortmannin. This product is intended for research and analytical applications. Wortmannin (SL-2052; KY-12420) is a potent, selective and irreversible PI3K inhibitor with an IC50 of 3 nM. Wortmannin also blocks autophagy formation, and potently inhibits Polo-like kinase 1 (PlK1) and Plk3 with IC50s of 5.8 and 48 nM, respectively .

Cat. No.	Product Name	Target	Research Area

HY-P99431

KY-1044 Alomfilimab; SAR 445256	CD28	Inflammation/Immunology Cancer
KY-1044 (Alomfilimab; SAR 445256) is a fully human IgG1 antibody targeting inducible costimulatory receptor (ICOS). KY-1044 depletes ICOS ^high cells via antibody-dependent cellular cytotoxicity (ADCC) through the engagement of FcgRIIIa. KY-1044 act as a costimulatory molecule on cells expressing lower ICOS levels, such as CD8 ⁺ T_Eff cells (through FcgR-dependent clustering). KY-1044 exploit the differential expression of ICOS on T-cell subtypes to improve the intratumoral immune contexture and restore an antitumor immune response .

HY-P99434

Amlitelimab KY1005; SAR445229	Inhibitory Antibodies	Inflammation/Immunology
Amlitelimab () is an anti-OX40 Ligand (OX40L) monoclonal antibody (mAb). Amlitelimab inhibits OX40-OX40L interaction, and can be used in the research of atopic dermatitis .

Wortmannin 125+ Cited Publications SL-2052; KY-12420	Human Gut Microbiota Metabolites Microorganisms Source classification Endogenous metabolite	Organoid PI3K Polo-like Kinase (PLK) Autophagy Antibiotic
Wortmannin (SL-2052; KY-12420) is a potent, selective and irreversible PI3K inhibitor with an IC₅₀ of 3 nM. Wortmannin also blocks autophagy formation, and potently inhibits Polo-like kinase 1 (PlK1) and Plk3 with IC₅₀s of 5.8 and 48 nM, respectively .

N-(2-hydroxy-2-phenylethyl)acetamide	Infection Structural Classification Natural Products Microorganisms Classification of Application Fields Source classification Disease Research Fields	Fungal
N-(2-hydroxy-2-phenylethyl)acetamide is isolated from the solid rice cultures of the endophytic fungus Diaporthe eucalyptorum KY-9. N-(2-hydroxy-2-phenylethyl)acetamide exhibits antifungal activities against Alternaria solani .

Wortmannin (Standard)	Human Gut Microbiota Metabolites Microorganisms Source classification Endogenous metabolite	Organoid PI3K Polo-like Kinase (PLK) Autophagy Antibiotic
Wortmannin (Standard) is the analytical standard of Wortmannin. This product is intended for research and analytical applications. Wortmannin (SL-2052; KY-12420) is a potent, selective and irreversible PI3K inhibitor with an IC50 of 3 nM. Wortmannin also blocks autophagy formation, and potently inhibits Polo-like kinase 1 (PlK1) and Plk3 with IC50s of 5.8 and 48 nM, respectively .

Cat. No.	Product Name		Classification

HY-147084

KY371		Alkynes
KY371 is a click chemistry reagent containing an alkyne group. KY371 is a broad-range glycosidase inhibitor. KY371 can combine with proteomic analysis of targeted protein to study glycosidases .

KY Human Pre-designed siRNA Set A		siRNAs Human Pre-designed siRNA Sets
KY Human Pre-designed siRNA Set A contains three designed siRNAs for KY gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks